# First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

> **NCT01437618** · — · COMPLETED · sponsor: **Azienda Ospedaliero, Universitaria Pisana** · enrollment: 15 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** FOLFOXIRI plus bevacizumab

## Key facts

- **NCT ID:** NCT01437618
- **Lead sponsor:** Azienda Ospedaliero, Universitaria Pisana
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** —
- **Final completion:** 2011-05
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2011-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01437618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01437618, "First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01437618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*